Already reeling under the pressure of protracted uncertainty over the acquisition of Baxalta and the ongoing political intervention on price gouging in the US pharma sector, Shire stumbled upon another roadblock on Friday when its blockbuster potential drug Lifitegrast was rejected by the FDA. The FDA has sought additional clinical trials in addition to information related to the drug quality. Management says the company remains committed to the drug and will re-file the submission in Q1 16 w
20 Oct 2015
No Lifitegrast in present form
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
No Lifitegrast in present form
Shires Income PLC GBP (SHRS:LON) | 225 -5.6 (-1.1%) | Mkt Cap: 93.1m
- Published:
20 Oct 2015 -
Author:
Kamla Singh -
Pages:
2
Already reeling under the pressure of protracted uncertainty over the acquisition of Baxalta and the ongoing political intervention on price gouging in the US pharma sector, Shire stumbled upon another roadblock on Friday when its blockbuster potential drug Lifitegrast was rejected by the FDA. The FDA has sought additional clinical trials in addition to information related to the drug quality. Management says the company remains committed to the drug and will re-file the submission in Q1 16 w